This contract expires in 266 days (Jan 8, 2027).
UTAH STATE UNIVERSITY - TO DETERMINE THE ANTIVIRAL INHIBITORY EFFECT USING ASSAYS SUCH AS CPE TO DETERMINE EC50; ASSAYS SUCH AS VYR/PR TO DETERMINE EC90, AND CYTOTOXICITY (CC50) OF EXPERIMENTAL COMPOUNDS AGAINST VIRUSES THAT REQUIRE A MAXIMUM BIOSAFETY LABORATORY CONTAINMEN
Key Details
Description
TO DETERMINE THE ANTIVIRAL INHIBITORY EFFECT USING ASSAYS SUCH AS CPE TO DETERMINE EC50; ASSAYS SUCH AS VYR/PR TO DETERMINE EC90, AND CYTOTOXICITY (CC50) OF EXPERIMENTAL COMPOUNDS AGAINST VIRUSES THAT REQUIRE A MAXIMUM BIOSAFETY LABORATORY CONTAINMEN
Contractor Information
Similar Awards
CLINICAL SERVICES NETWORK- CLINICAL TRIAL PLANNING AND EXECUTION
ALLUCENT GOVERNMENT SERVICES (US) LLC
$370.1M
CLINICAL SERVICES NETWORK- CLINICAL TRIAL PLANNING AND EXECUTION
ICON GOVERNMENT AND PUBLIC HEALTH SOLUTIONS, INC.
$330.2M
CLINICAL SERVICES NETWORK- CLINICAL TRIAL PLANNING AND EXECUTION
TECHNICAL RESOURCES INTERNATIONAL, INC.
$317.1M
ANTIBIOTIC FOR TREATMENT OF A BIOTHREAT INDICATION
PARATEK PHARMACEUTICALS, INC
$265.3M
ASPR-18-04963 -- FUNDING FOR BALOXAVIR MARBOXIL ACTIVITIES FOR BASE PERIOD TASK UNDER THE GENENTECH OTA
GENENTECH INC
$243.7M
Stay Updated
Get notified about new opportunities matching your interests.